Advanced Research in Neuroprotection: 2nd Edition

A Special Issue of Biomedicines (ISSN 2227-9059) belonging to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 27 March 2027 | Viewed by 907

Editors


E-Mail
Guest Editor
Laboratory of Experimental Neurology and Neuroimmunology, 2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
Interests: neuroimmunology; experimental neurology; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite their privileged nature, the central and peripheral nervous systems may suffer injury and are vulnerable to immune attacks. Neuroinflammatory manifestations accompany alterations to the microenvironment, which may lead to neuronal dysregulation and the appearance of neurological disorders. Despite the distinct entity of each nervous system disease, they share common pathological traits, such as biochemical damage, oxidative stress, axonal loss, and neuronal death, thus revealing the essential role of neuroprotective pathways in ensuring neuronal homeostasis and longevity. Breakthroughs in the field of drug desig and neuropharmacology along with the latest progress in animal and human models have shown the utility of translational medicine, advocating for more appropriate strategies and pharmacologic agents that can mediate the task of neuroprotection.

This Special Issue, entitled “Advanced Research in Neuroprotection: 2nd Edition”, invites original research articles, short reports, and reviews that will expertly present recent advances in both experimental and clinical knowledge of neuroprotective mechanisms and strategies within various neurological disorders.

Dr. Christos Bakirtzis
Dr. Evangelia Kesidou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuroprotection
  • neurodegeneration
  • neuroinflammation
  • axonal loss
  • neuropharmacology
  • traumatic brain injury
  • blood–brain barrier

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 3036 KB  
Review
Targeting the Complement–Microglia Axis for Neuroprotection in Pediatric Epilepsy
by Marah Karayanni, Nikolaos Mitsoudis, Maria Vanakliotou, Christos Bakirtzis, Evangelia Kesidou, Eleni Polyzoidou and Ekaterini Liana
Biomedicines 2026, 14(8), 1788; https://doi.org/10.3390/biomedicines14081788 - 8 Aug 2026
Viewed by 500
Abstract
Neuroprotection in childhood developmental and epileptic encephalopathies may require approaches, distinct from adult brain injury models of neuroprotection, with a primary focus on preservation of synaptic density rather than prevention of cellular necrosis. There is growing evidence to indicate early-life seizures activate complement [...] Read more.
Neuroprotection in childhood developmental and epileptic encephalopathies may require approaches, distinct from adult brain injury models of neuroprotection, with a primary focus on preservation of synaptic density rather than prevention of cellular necrosis. There is growing evidence to indicate early-life seizures activate complement cascade proteins C1q and C3. Subsequently, localized microglia may excessively phagocytose structurally intact synaptic neurons disrupting normal brain maturation. This review incorporates kinetic models of neuro-immune interactions based on human histopathology from epileptogenic tissues and quantitative neuro-immune biomarkers to provide suggestions that complement-mediated synaptic pruning may contribute to structural network disruption and cognitive decline in pediatric epilepsy. While standard anti-seizure medications effectively stabilize electrical activity, they do not mitigate underlying neuro-inflammatory responses. Consequently, targeted pharmacological inhibition of the complement microglia axis may provide a potential disease modifying strategy to protect developing neural circuits. The translational feasibility of using targeted complement inhibitors should be evaluated addressing critical challenges such as central nervous system drug delivery across the blood–brain barrier, immunosuppression management and the application of non-invasive biomarkers to define the precise therapeutic window for intervention. Full article
(This article belongs to the Special Issue Advanced Research in Neuroprotection: 2nd Edition)
Show Figures

Graphical abstract

Back to TopTop